share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q:2024財年三季報
美股SEC公告 ·  05/15 13:35

Moomoo AI 已提取核心訊息

Incannex Healthcare Inc., a biopharmaceutical company, reported its financial results for the quarter ended March 31, 2024. The company experienced an increase in operating expenses, primarily due to higher research and development costs associated with clinical trials. Research and development expenses rose by $1.6 million compared to the same period in the previous year, reaching $3.3 million. General and administrative expenses also increased by $2.1 million, totaling $4.1 million for the quarter. This rise was attributed to higher salaries and employee benefits, including the issuance of restricted stock, as well as increased legal and accounting expenses following the company's re-domiciliation. Despite these increases, the company benefited from a $1.3 million R&D tax credit. The net loss for the quarter was $6.0 million, a significant increase...Show More
Incannex Healthcare Inc., a biopharmaceutical company, reported its financial results for the quarter ended March 31, 2024. The company experienced an increase in operating expenses, primarily due to higher research and development costs associated with clinical trials. Research and development expenses rose by $1.6 million compared to the same period in the previous year, reaching $3.3 million. General and administrative expenses also increased by $2.1 million, totaling $4.1 million for the quarter. This rise was attributed to higher salaries and employee benefits, including the issuance of restricted stock, as well as increased legal and accounting expenses following the company's re-domiciliation. Despite these increases, the company benefited from a $1.3 million R&D tax credit. The net loss for the quarter was $6.0 million, a significant increase from the $3.6 million loss reported in the previous year. The company's cash position stood at $9.3 million as of March 31, 2024. Incannex Healthcare's business development efforts included the continuation of clinical trials for its drug candidates. Looking ahead, the company plans to further its research and development activities and pursue regulatory approvals for its products.
生物製藥公司Incannex Healthcare Inc.公佈了截至2024年3月31日的財務報告。該公司營業費用增加,主要由於臨床試驗相關的研發成本增加。與上一年同期相比,研發費用增長了160萬美元,達到330萬美元。總行政費用也增加了210萬美元,本季度總共爲410萬美元。這一增長歸因於工資和員工福利(包括髮行受限股票)增加以及公司重新設立後法律和會計費用的增加。儘管有這些增加,該公司獲得了130萬美元的研發稅收抵免。本季度淨損失爲600萬美元,大幅增加了上一年報告的360萬美元的虧損。截至2024年3月31日,該公司的現金狀況爲930萬美元。Incannex Healthcare的業務發展包括繼續開展其藥物候選品的臨床試驗。展望未來,公司計劃進一步開展研發活動並尋求其產品的監管批准。
生物製藥公司Incannex Healthcare Inc.公佈了截至2024年3月31日的財務報告。該公司營業費用增加,主要由於臨床試驗相關的研發成本增加。與上一年同期相比,研發費用增長了160萬美元,達到330萬美元。總行政費用也增加了210萬美元,本季度總共爲410萬美元。這一增長歸因於工資和員工福利(包括髮行受限股票)增加以及公司重新設立後法律和會計費用的增加。儘管有這些增加,該公司獲得了130萬美元的研發稅收抵免。本季度淨損失爲600萬美元,大幅增加了上一年報告的360萬美元的虧損。截至2024年3月31日,該公司的現金狀況爲930萬美元。Incannex Healthcare的業務發展包括繼續開展其藥物候選品的臨床試驗。展望未來,公司計劃進一步開展研發活動並尋求其產品的監管批准。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息